Emtricitabine Seminal Plasma and Blood Plasma Population Pharmacokinetics in HIV-Infected Men in the EVARIST ANRS-EP 49 Study
暂无分享,去创建一个
C. Rouzioux | S. Urien | M. Suzan-Monti | N. Bouazza | L. Assoumou | J. Treluyer | S. Illamola | M. De Sousa Mendes | Gabrielle Lui | D. Hirt | E. Valade | F. Foissac | C. Chenevier-Gobeaux | J. Viard | J. Ghosn | G. Lui | Elodie Valade
[1] N. Dejucq-Rainsford,et al. Origins of HIV-infected leukocytes and virions in semen. , 2014, The Journal of infectious diseases.
[2] C. Rouzioux,et al. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] F. Ceccherini‐Silberstein,et al. Understanding HIV Compartments and Reservoirs , 2014, Current HIV/AIDS Reports.
[4] S. Urien,et al. Population Pharmacokinetics of Emtricitabine in HIV-1-Infected Adult Patients , 2014, Antimicrobial Agents and Chemotherapy.
[5] M. Nicol,et al. Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women , 2012, Clinical Pharmacokinetics.
[6] K. Mayer,et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men , 2012, AIDS.
[7] V. Calvez,et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002–2011 survey , 2012, AIDS.
[8] R. Bendayan,et al. Expression of ATP-Binding Cassette Membrane Transporters in Rodent and Human Sertoli Cells: Relevance to the Permeability of Antiretroviral Therapy at the Blood-Testis Barrier , 2012, Journal of Pharmacology and Experimental Therapeutics.
[9] Myron S. Cohen,et al. Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission , 2011, Science Translational Medicine.
[10] S. Khoo,et al. Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract , 2011, Antiviral therapy.
[11] Stephen Taylor,et al. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV , 2010, Current opinion in HIV and AIDS.
[12] P. Halfon,et al. Semen may harbor HIV despite effective HAART: another piece in the puzzle , 2010, Retrovirology.
[13] R. Kaul,et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy , 2009, AIDS.
[14] Matthias Egger,et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.
[15] D. Taft,et al. Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. , 2008, Journal of pharmaceutical sciences.
[16] R. Farinotti,et al. Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] M. Batterham,et al. Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. , 2008, Current HIV research.
[18] Myron S. Cohen,et al. Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine in Semen and Plasma of HIV-1-Infected Men , 2008, Journal of acquired immune deficiency syndromes.
[19] Don E. Smith,et al. Relationship between HIV-RNA load in blood and semen in antiretroviral-naïve and experienced men and effect of asymptomatic sexually transmissible infections. , 2008, Current HIV research.
[20] G. Chittick,et al. Pharmacokinetic Evaluation of Emtricitabine in Combination With Other Nucleoside Antivirals in Healthy Volunteers , 2007, Journal of clinical pharmacology.
[21] G. Chittick,et al. Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers , 2007, Journal of clinical pharmacology.
[22] Marc Lavielle,et al. Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..
[23] F. Rousseau,et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.
[24] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[25] P. Vernazza,et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV , 2000, AIDS.